LATEST NEWS

New drug candidate showed efficacy in human endometriosis samples

Our collaborators from the University of Maastricht have published the study titled: “Inhibition of type 1 17β-hydroxysteroid dehydrogenase impairs the synthesis of 17β-estradiol in endometriosis lesions.”

In this study Andrea Romano and his team studied the efficacy of Forendo’s new drug candidate in human endometriosis samples. The results showed that the expression of HSD17B1 enzyme, converting estrone (weak estrogen) to estradiol (potent estrogen), is associated with the higher estrogen synthesis in endometriosis than in the endometrium inside the uterus. With the specific HSD17B1 enzyme inhibitor the estradiol production was efficienly decreased in more than 70% of studied endometriosis patient biopsy samples. Click here to see the abstract!

Categories: HSD